These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Inflammation and the development of atherosclerosis. Mizuno Y; Jacob RF; Mason RP J Atheroscler Thromb; 2011; 18(5):351-8. PubMed ID: 21427505 [TBL] [Abstract][Full Text] [Related]
6. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031 [TBL] [Abstract][Full Text] [Related]
7. Using Machine Learning to Evaluate the Role of Microinflammation in Cardiovascular Events in Patients With Chronic Kidney Disease. Liu XQ; Jiang TT; Wang MY; Liu WT; Huang Y; Huang YL; Jin FY; Zhao Q; Wang GH; Ruan XZ; Liu BC; Ma KL Front Immunol; 2021; 12():796383. PubMed ID: 35082785 [TBL] [Abstract][Full Text] [Related]
8. Uremic Toxins, Oxidative Stress, Atherosclerosis in Chronic Kidney Disease, and Kidney Transplantation. Wojtaszek E; Oldakowska-Jedynak U; Kwiatkowska M; Glogowski T; Malyszko J Oxid Med Cell Longev; 2021; 2021():6651367. PubMed ID: 33628373 [TBL] [Abstract][Full Text] [Related]
10. Statins attenuate the development of atherosclerosis and endothelial dysfunction induced by exposure to urban particulate matter (PM10). Miyata R; Hiraiwa K; Cheng JC; Bai N; Vincent R; Francis GA; Sin DD; Van Eeden SF Toxicol Appl Pharmacol; 2013 Oct; 272(1):1-11. PubMed ID: 23756175 [TBL] [Abstract][Full Text] [Related]
11. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. Katsiki N; Mikhailidis DP; Banach M Expert Opin Pharmacother; 2019 Nov; 20(16):2007-2017. PubMed ID: 31344332 [No Abstract] [Full Text] [Related]
12. Potential vascular benefits of statins. Kinlay S Am J Med; 2005 Dec; 118 Suppl 12A():62-7. PubMed ID: 16356810 [TBL] [Abstract][Full Text] [Related]
13. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Lahera V; Goicoechea M; de Vinuesa SG; Miana M; de las Heras N; Cachofeiro V; Luño J Curr Med Chem; 2007; 14(2):243-8. PubMed ID: 17266583 [TBL] [Abstract][Full Text] [Related]
14. Statins and Cardiovascular Disease Outcomes in Chronic Kidney Disease: Reaffirmation vs. Repudiation. Obialo CI; Ofili EO; Norris KC Int J Environ Res Public Health; 2018 Dec; 15(12):. PubMed ID: 30518032 [TBL] [Abstract][Full Text] [Related]
15. Statins: 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors demonstrate anti-atherosclerotic character due to their antioxidant capacity. Puttananjaiah MK; Dhale MA; Gaonkar V; Keni S Appl Biochem Biotechnol; 2011 Jan; 163(2):215-22. PubMed ID: 20640529 [TBL] [Abstract][Full Text] [Related]